Navigation Links
Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports
Date:7/22/2014

New York, NY (PRWEB) July 22, 2014

The Pennsylvania judge overseeing hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) in the Philadelphia Court of Common Pleas won’t reconsider his decision to deny punitive damages in cases alleging the medication caused plaintiffs to develop gynecomastia (male breast growth), Bernstein Liebhard LLP reports. In an Order dated July 18, 2014, Judge Arnold New also denied a plaintiffs’ request to certify the matter for an immediate appeal to the Pennsylvania Superior Court. (In Re: Risperdal Litigation, Case Number 100300296)

In May, Judge New had ruled that the New Jersey Product Liability Act would be applied to the Risperdal lawsuits, as the manufacturer of the medication is based in New Jersey. In disallowing punitive damage claims, the Order noted that the Act does not allow punitive damage awards in cases involving medications that were approved by the U.S. Food & Drug Administration.

“Our Firm is representing a number of clients who have filed Risperdal gynecomastia claims in this proceeding. It is important that all plaintiffs involved in this litigation understand that this latest decision does not in any way bar them from seeking compensatory damages. Their Risperdal lawsuits will continue to move forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Gynecomastia Litigation
Court documents indicate that more than 600 Risperdal lawsuits are pending in Pennsylvania, hundreds of which were filed on behalf of men and boys who allegedly developed gynecomastia due to the atypical antipsychotic. All of the lawsuits assert that Johnson & Johnson and its Janssen Pharmaceuticals unit were aware of the alleged association between Risperdal and gynecomastia, but concealed this knowledge from doctors and patients. The companies are also accused of improperly promoting the off-label use of Risperdal in children long before any pediatric indications were approved in 2006.

In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to resolve criminal and civil charges brought by the U.S. Department of Justice regarding the marketing of Risperdal and other drugs. According to court documents filed in the case, federal prosecutors had alleged that the companies concealed side effects associated with the medication, including an association with elevated levels of prolactin, a hormone associated with breast development and lactation. The Justice Department also accused the companies of improperly marketing Risperdal for pediatric uses. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be entitled to file their own claim against Johnson & Johnson and Janssen. To learn more about the possible association between Risperdal and male breast growth, please visit Bernstein Liebhard LLPs website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb12037548.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Risperdal Lawsuit Website Published by Bernstein Liebhard LLP; Provides Side Effect Information, Litigation Updates
2. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes New Report Detailing Increasing Use of Risperdal and other Antipsychotic Drugs Among Children
3. Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data
4. Risperdal Lawsuits Progress, as Bernstein Liebhard LLP Notes Filing of Plaintiff Brief Seeking to Unseal Risperdal Clinical Studies
5. As Risperdal Lawsuits Move Forward, Wright & Schulte LLC Learns of Bid to Keep Clinical Studies Sealed in Pennsylvania Risperdal Litigation
6. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
7. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Federal Award to Risperdal Whistleblower
8. As Risperdal Lawsuits Move Forward, Bernstein Liebhard LLP Launches Website to Provide Information Regarding Alleged Association Between Risperdal and Gynecomastia
9. Plaintiffs in 77 Risperdal Gynecomastia Lawsuits File Motion to Force J&J to Comply with Existing Settlement Agreement, Reviewed By Wright & Schulte LLC
10. Risperdal Lawsuit News: Bernstein Liebhard LLP Comments on Release of Emails from Johnson & Johnson’s Janssen Subsidiary in Federal Risperdal Settlement
11. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Mounting Claims Involving Risperdal Gynecomastia Allegations in Pennsylvania Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... York, New York (PRWEB) , ... ... ... International Courier, LLC, d/b/a Quick International, LLC (“Quick”), a highly specialized asset-light ... announced it has entered into a definitive agreement to purchase Unitrans International ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry ... educational webinar, they will present the line of epMotion automated liquid handling system. ... you can automate everyday pipetting tasks. , Ideal for scientists and lab technicians ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston area ... Texas, is launching a regional charity effort to provide publicity assistance and generate ... Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that has ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... Boca Raton (PRWEB) , ... August 18, 2017 , ... ... is continuing to ramp up its marketing efforts with its product now available through ... hangover remedy to the public. The effervescent powdered drink is designed to quickly detox ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology: